Prevalence of bortezomib-resistant constitutive NF-kappaB activity in mantle cell lymphoma

<p>Abstract</p> <p>Background</p> <p>The proteasome inhibitor bortezomib can inhibit activation of the transcription factor NF-κB, a mechanism implicated in its anti-neoplastic effects observed in mantle cell lymphoma (MCL). However, NF-κB can be activated through many...

Täydet tiedot

Bibliografiset tiedot
Päätekijät: Kahl Brad S, Young Ken H, Yang David T, Markovina Stephanie, Miyamoto Shigeki
Aineistotyyppi: Artikkeli
Kieli:English
Julkaistu: BMC 2008-05-01
Sarja:Molecular Cancer
Linkit:http://www.molecular-cancer.com/content/7/1/40